Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. / Nielsen, C U; Amstrup, J; Steffansen, B; Frokjaer, S; Brodin, Birger.

In: American Journal of Physiology: Gastrointestinal and Liver Physiology, Vol. 281, No. 1, 2001, p. G191-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nielsen, CU, Amstrup, J, Steffansen, B, Frokjaer, S & Brodin, B 2001, 'Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line', American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 281, no. 1, pp. G191-9.

APA

Nielsen, C. U., Amstrup, J., Steffansen, B., Frokjaer, S., & Brodin, B. (2001). Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. American Journal of Physiology: Gastrointestinal and Liver Physiology, 281(1), G191-9.

Vancouver

Nielsen CU, Amstrup J, Steffansen B, Frokjaer S, Brodin B. Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. American Journal of Physiology: Gastrointestinal and Liver Physiology. 2001;281(1):G191-9.

Author

Nielsen, C U ; Amstrup, J ; Steffansen, B ; Frokjaer, S ; Brodin, Birger. / Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. In: American Journal of Physiology: Gastrointestinal and Liver Physiology. 2001 ; Vol. 281, No. 1. pp. G191-9.

Bibtex

@article{a1ab53ed9ae64647a84e19cc270924ea,
title = "Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line",
abstract = "The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [(14)C]glycylsarcosine ([(14)C]Gly-Sar) up to 50.2 +/- 3.6% (n = 6) of control values. Kinetic analysis of the fluxes showed that maximal flux (V(max)) of transepithelial transport decreased from 3.00 +/- 0.17 nmol x cm(-2) x min(-1) in control cells to 0.50 +/- 0.07 nmol x cm(-2) x min(-1) in cells treated with 5 ng/ml EGF (n = 6, P <0.01). The apparent Michaelis-Menten constant (K(m)) was 2.71 +/- 0.31 mM (n = 6) in control cells and 1.89 +/- 0.28 mM (n = 6, not significantly different from control) in EGF-treated cells. Similarly, apical uptake of [(14)C]Gly-Sar decreased in cells treated with EGF, with an ED(50) value of 0.36 +/- 0.06 ng/ml (n = 6) EGF and a maximal inhibition of 80 +/- 0.02% (n = 6). V(max) decreased from 2.61 +/- 0.4 to 1.06 +/- 0.1 nmol x cm(-2) x min(-1) (n = 3, P <0.05), whereas K(m) remained constant. Basolateral Gly-Sar uptake showed no changes in V(max) or K(m) after EGF treatment (n = 3). RT-PCR showed a decrease in hPepT1 mRNA (using glucose-6-phosphate dehydrogenase mRNA as control) in cells treated with EGF. Western blotting indicated a decrease in hPepT1 protein in cell lysates. We conclude that EGF treatment decreases Gly-Sar transport in Caco-2 cells by decreasing the number of peptide transporter molecules in the apical membrane.",
keywords = "Biological Transport, Caco-2 Cells, Carbon Radioisotopes, Carrier Proteins, Dipeptides, Dose-Response Relationship, Drug, Epidermal Growth Factor, Gene Expression, Humans, Immunohistochemistry, Intestinal Mucosa, Microscopy, Confocal, RNA, Messenger, Symporters",
author = "Nielsen, {C U} and J Amstrup and B Steffansen and S Frokjaer and Birger Brodin",
year = "2001",
language = "English",
volume = "281",
pages = "G191--9",
journal = "American Journal of Physiology: Gastrointestinal and Liver Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "1",

}

RIS

TY - JOUR

T1 - Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line

AU - Nielsen, C U

AU - Amstrup, J

AU - Steffansen, B

AU - Frokjaer, S

AU - Brodin, Birger

PY - 2001

Y1 - 2001

N2 - The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [(14)C]glycylsarcosine ([(14)C]Gly-Sar) up to 50.2 +/- 3.6% (n = 6) of control values. Kinetic analysis of the fluxes showed that maximal flux (V(max)) of transepithelial transport decreased from 3.00 +/- 0.17 nmol x cm(-2) x min(-1) in control cells to 0.50 +/- 0.07 nmol x cm(-2) x min(-1) in cells treated with 5 ng/ml EGF (n = 6, P <0.01). The apparent Michaelis-Menten constant (K(m)) was 2.71 +/- 0.31 mM (n = 6) in control cells and 1.89 +/- 0.28 mM (n = 6, not significantly different from control) in EGF-treated cells. Similarly, apical uptake of [(14)C]Gly-Sar decreased in cells treated with EGF, with an ED(50) value of 0.36 +/- 0.06 ng/ml (n = 6) EGF and a maximal inhibition of 80 +/- 0.02% (n = 6). V(max) decreased from 2.61 +/- 0.4 to 1.06 +/- 0.1 nmol x cm(-2) x min(-1) (n = 3, P <0.05), whereas K(m) remained constant. Basolateral Gly-Sar uptake showed no changes in V(max) or K(m) after EGF treatment (n = 3). RT-PCR showed a decrease in hPepT1 mRNA (using glucose-6-phosphate dehydrogenase mRNA as control) in cells treated with EGF. Western blotting indicated a decrease in hPepT1 protein in cell lysates. We conclude that EGF treatment decreases Gly-Sar transport in Caco-2 cells by decreasing the number of peptide transporter molecules in the apical membrane.

AB - The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [(14)C]glycylsarcosine ([(14)C]Gly-Sar) up to 50.2 +/- 3.6% (n = 6) of control values. Kinetic analysis of the fluxes showed that maximal flux (V(max)) of transepithelial transport decreased from 3.00 +/- 0.17 nmol x cm(-2) x min(-1) in control cells to 0.50 +/- 0.07 nmol x cm(-2) x min(-1) in cells treated with 5 ng/ml EGF (n = 6, P <0.01). The apparent Michaelis-Menten constant (K(m)) was 2.71 +/- 0.31 mM (n = 6) in control cells and 1.89 +/- 0.28 mM (n = 6, not significantly different from control) in EGF-treated cells. Similarly, apical uptake of [(14)C]Gly-Sar decreased in cells treated with EGF, with an ED(50) value of 0.36 +/- 0.06 ng/ml (n = 6) EGF and a maximal inhibition of 80 +/- 0.02% (n = 6). V(max) decreased from 2.61 +/- 0.4 to 1.06 +/- 0.1 nmol x cm(-2) x min(-1) (n = 3, P <0.05), whereas K(m) remained constant. Basolateral Gly-Sar uptake showed no changes in V(max) or K(m) after EGF treatment (n = 3). RT-PCR showed a decrease in hPepT1 mRNA (using glucose-6-phosphate dehydrogenase mRNA as control) in cells treated with EGF. Western blotting indicated a decrease in hPepT1 protein in cell lysates. We conclude that EGF treatment decreases Gly-Sar transport in Caco-2 cells by decreasing the number of peptide transporter molecules in the apical membrane.

KW - Biological Transport

KW - Caco-2 Cells

KW - Carbon Radioisotopes

KW - Carrier Proteins

KW - Dipeptides

KW - Dose-Response Relationship, Drug

KW - Epidermal Growth Factor

KW - Gene Expression

KW - Humans

KW - Immunohistochemistry

KW - Intestinal Mucosa

KW - Microscopy, Confocal

KW - RNA, Messenger

KW - Symporters

M3 - Journal article

C2 - 11408272

VL - 281

SP - G191-9

JO - American Journal of Physiology: Gastrointestinal and Liver Physiology

JF - American Journal of Physiology: Gastrointestinal and Liver Physiology

SN - 0193-1857

IS - 1

ER -

ID: 37899733